A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease

NCT ID: NCT00498212

Last Updated: 2019-03-26

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 41 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-07-31
• Study Completion Date: 2008-10-31

Brief Summary

The purpose of this study is to find out if a new investigational hepatitis B virus (HBV) vaccine, HEPLISAV™, is safe and effective for end-stage renal disease (ESRD) patients. Two dose levels will be studied: a single dose and a double dose. We expect both dose levels to safely immunize patients against HBV. The study will determine which dose does this best.

Detailed Description

Infection with hepatitis B virus (HBV) is a major global health problem. Worldwide, it is estimated that 2 billion people have been infected previously and 350 million are chronically infected. While acute HBV infection is associated with significant illness, the risk of chronic infection is of great importance since 5-10% of infected adults will not clear the infection after the initial phase of the illness. About 25% of people who do not initially clear the infection will later develop chronic active hepatitis.

This study will evaluate the safety and immunogenicity of HEPLISAV™ when administered to adults who have end-stage renal disease (glomerular filtration rate [GFR] ≤ 45 mL/min). Once subjects have been consented, screened, and randomized to treatment, subjects will receive a total of three injections over a 24-week period, with follow-up visits at 28 and 50 weeks. Subjects will receive 1 of the following 2 regimens:

• HEPLISAV™ single dose at Day 0, 4 weeks (1 month) and 24 weeks (6 months)
• HEPLISAV™ double dose at Day 0, 4 weeks (1 month) and 24 weeks (6 months)

Safety and tolerability will be evaluated by occurrence of adverse events, periodic laboratory tests, vital signs, and local and systemic reactogenicity.

Immunogenicity will be evaluated by the proportion of subjects exhibiting a seroprotective immune response (anti-hepatitis B surface antigen antibodies [anti-HBsAg] ≥ 10 milli-international unit (mIU)/mL) at Weeks 4, 12, 24, 28 and 50.

Conditions

Hepatitis B

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: SINGLE

Study Groups

1018 ISS-HBsAg-Single

Single dose (3000 µg 1018 ISS + 20 µg rHBsAg)

Group Type: EXPERIMENTAL

1018 ISS-HBsAg-Single

Intervention Type: BIOLOGICAL

Intramuscular (IM) injection at Day 0, Week 4 and Week 24

1018 ISS-HBsAg-Double

Double dose (6000 µg 1018 ISS + 40 µg rHBsAg)

Group Type: EXPERIMENTAL

1018 ISS-HBsAg-Double

Intervention Type: BIOLOGICAL

Intramuscular (IM) injection at Day 0, Week 4 and Week 24

Interventions

1018 ISS-HBsAg-Single

Intramuscular (IM) injection at Day 0, Week 4 and Week 24

Intervention Type: BIOLOGICAL

1018 ISS-HBsAg-Double

Intramuscular (IM) injection at Day 0, Week 4 and Week 24

Intervention Type: BIOLOGICAL

Other Intervention Names

HEPLISAV™; HEPLISAV™

Eligibility Criteria

Inclusion Criteria

• Willing and able to give written informed consent
• Have a glomerular filtration rate (GFR) ≤ 45 mL/min
• Have an expectation of going on hemodialysis or are already on hemodialysis
• Is serum negative for hepatitis B virus (HBV) antibodies, hepatitis C virus (HCV), and human immunodeficiency virus (HIV)
• Have repeated resting blood pressure measurements ≤ 165/105 mmHg
• Women of childbearing potential must be consistently using a highly effective method of birth control

Exclusion Criteria

• Women who are pregnant, breastfeeding or planning a pregnancy
• Any previous HBV infection
• Previous vaccination (1 or more doses) with any HBV vaccine
• Any previous autoimmune diseases
• Have a diagnosis of chronic renal failure due to autoimmune disease
• Are at high risk for recent exposure to HBV, HCV or HIV
• Received any antibodies within 3 months prior to study entry
• Ever received an injection with DNA plasmids or oligonucleotides
• Received any vaccines within 4 weeks prior to study entry
• Received any other investigational medicinal agent within 4 weeks prior to study entry

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Dynavax Technologies Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Eduardo Martins, MD, D Phil

Role: STUDY_DIRECTOR

Dynavax Technologies Corporation

Locations

White Hills Medical Clinic

St. John's, Newfoundland and Labrador, Canada

QEII Health Sciences Centre

Halifax, Nova Scotia, Canada

SMBD - Jewish General Hospital

Montreal, Quebec, Canada

Countries

Canada

Related Links

http://www.dynavax.com

Dynavax Webpage

Other Identifiers

DV2-HBV-11

Identifier Type: -

Identifier Source: org_study_id